PolyPeptide Group AG

PolyPeptide Group AG is a specialized contract development and manufacturing organization (CDMO) with a focus on peptide- and oligonucleotide-based active pharmaceutical ingredients. Serving primarily pharmaceutical and biotechnology companies, its core function is to support clients in bringing peptide and oligonucleotide drug therapies from early development through commercial manufacturing. PolyPeptide’s extensive expertise covers treatments for a wide array of conditions, with a pronounced presence in metabolic diseases such as diabetes and obesity, as well as therapies for cancer, cardiovascular, and neurological disorders. Since its establishment in 1952, the company has grown into a global player with manufacturing facilities across Europe, the United States, and India, and a workforce exceeding 1,300 employees. Its longstanding reputation is built on advanced technical capabilities, rigorous quality standards (GMP compliance), and deep experience in supporting regulatory approvals and successful product launches. PolyPeptide Group AG plays a critical role within the healthcare sector by enabling innovation and reliable supply of therapeutic peptides, reflecting its significance in advancing modern pharmaceutical and biotech markets.